Most drug delivery systems as treatment modalities for osteomyelitis have not been evaluated for resistant infections. Tigecycline (TG) is an antimicrobial agent that could be used in the treatment of multi-drug-resistant orthopedic infections. The objective of this in vitro study has been to determine what dosage of TG causes changes in the morphology and number of osteoblasts. We have also investigated whether nanoparticulate tigecycline-loaded calcium-phosphate/poly(DL-lactide-co-glycolide) is biocompatible and whether it could release bioactive TG in a controlled manner during the observation time. The cytotoxicity was tested by analyzing the release of lactate dehydrogenase from dead osteoblasts to the medium. Staphylococcus aureus was used to verify the antibacterial effect of the multifunctional drug delivery system. At concentrations as achieved by local application, TG caused high toxic effect and impaired the normal osteoblastic morphology. The nanoparticulate multifunctional drug delivery system showed good compatibility and antibacterial effect during the observation time and thus appears to be suitable for the treatment of osteomyelitis caused by multi-drug-resistant microbes.
Introduction
The septic disease osteomyelitis represents the worst complication in orthopedic surgery and traumatology. It is difficult to ensure effective bone transplantation and to treat the infection at the same time. The systemic administration of antibiotics cannot provide sufficient local drug concentration and long-term administration may cause side-effects.
In patients with bone defects, such treatments must have two stages, i.e. the control of the infection, as the first, and bone grafting as the second stage. In recent years, diverse antibiotic delivery systems have been developed as treatment modalities in infectious bone injuries or chronic osteomyelitis. Their advantage rests in the possibility to achieve a high local antibiotic concentration without exposing the patient to systemic toxic levels [1] [2] [3] [4] [5] [6] . Most antibiotic delivery systems have not been evaluated for unusual or resistant infections and their impact remains limited in the rapidly changing field of orthopedic microorganisms. Finally, once drug elution has tapered off, the carrier becomes another foreign body that fosters bacterial colonization.
Multifunctional drug delivery systems (MDDS) are designed with the idea of ensuring a slow release of the drug, the elimination of the drug carrier and regeneration of the place at which the implant was placed. Poly(d,l-lactide-co-glycolide) (PLGA) is a biodegradable polymer with non-toxic degradation products that are easily removed from the organism by natural metabolite pathways. Nanoparticulate systems based on PLGA have also been the subject of research in the treatment of osteomyelitis. Calciumphosphate (CP) is chemically similar to the mineral component of bones and it has the capacity to promote and stimulate the regeneration of bone tissue [7] [8] [9] [10] .
Multifunctional nano drug delivery systems (MNDDS) for the controlled drug delivery reference to calibrate the spectrophotometer. LDH activities were calculated in percentage of the LDH activity against the total cell death induced by 1% Triton X-100 treatments (control).
Tigecycline treatment
Tigecycline antibiotic powder (Wyeth, USA) was solubilized following the manufacturers' instructions to obtain six different concentrations (0, 0.5, 5, 50, 250, and 500 μg/ml). The attachment of cells to the bottom of the culture plates was achieved after 24 h. The cells were incubated for another 24, 48 or 72 h before the assessment of the cell cytotoxicity and morphology. The cell medium was changed after 24 hours. The number of cells was 300,000 or 300,000 per hole in 1 ml. The results were expressed as a ratio of released LDH to the amount of untreated control cells.
CP/PLGA tigecycline treatment
After 24 h, the attachment of cells was achieved, the medium was removed, and 1 ml of fresh medium was added to each well containing 0.02 g pulver of CP/PLGA (without tigecycline), CP/PLGA/TG0.6 and CP/PLGA/TG5 [21] . Cells were then incubated for another 24, 48, and 72 h before the assessment of the cell cytotoxicity. We attempted to describe through quantitative parameters the manner in which extracts from CP/PLGA, CP/PLGA/TG0.6 and CP/PLGA/TG5 induce the LDH activity in the extracellular space. The medium was changed after 24, 48 and 72h.
Morphology
The morphology of the cells cultivated with different concentrations of TG and of those from the control (without tigecycline) culture were examined after 24, 48 and 72 hours using a light microscope with a 10x and a 40x objective (Olympus 1x70, Hamburg, Germany).
Verification of the microbiological activity of tigecycline-loaded CP/PLGA
In order to test the antibacterial activity of the released TG from tigecycline-loaded CP/PLGA, the growth inhibition of the most common organism causing osteomyelitis, S. aureus, was used [20, 31] . Staphylococcus aureus ATCC 10832 was inoculated on the surface of nutrient agar plates. Six sterile blank 6-mm paper discs were placed on the surface of each inoculated agar plate. Each disc was loaded with 50μl of the standard TG solutions and incubated for 24 h, after which the diameters of the zones of complete inhibition (including the diameter of the disc) were recorded in millimeters. The concentrations were then plotted on a semilogarithmic scale versus their corresponding zone diameters to give a standard curve. Six-millimeters discs of CP/PLGA, CP/PLGA/TG0.6 and CP/PLGA/TG5 were incubated in sterile saline for 24 h, seven, 14 and 21 days and after that, they were applied in triplicate to the prepared bioassay agar plates incubated at 30°C for 24 hours. The diameters of the zones of inhibition for the standards and the samples were measured manually. The six measurements per zone of inhibition (three measurements per sample × two replicates) were averaged. The concentrations of the samples were determined by comparing the mean zone size of the samples to the zone sizes of the standard curve and their corresponding concentrations.
All measurements were documented with photos and performed by a person who was not involved in the research.
Statistical analysis
The statistical analysis was performed using the software package Sigma Plot version 11.0. Groups of data were evaluated using a one-way analysis of variance (ANOVA) followed by the Kruskal-Wallis tests for all pair wise multiple comparisons or Dunn's for multiple comparisons versus the control group. The significance was set at p < 0.001. The data were presented as the mean ± standard error. All experiments were done thrice with a minimum of four samples for each concentration and parameter.
Results

Tigecycline-loaded calcium phosphate/poly-DL-lactide-co-glycolide basic analysis
Difraktogram of tigecycline-loaded calcium phosphate/poly-DL-lactide-co-glycolide loaded with 5wt% tigecycline (specimens with maximum ratio of TG) is shown in Figure 1a . In Figure 1b shows the FT-IR spectrum of the same material.
The most intense peaks, in Figure 1a , at 31.8 0 (2 1 1), 32.2 0 (1 1 2), 32.9 0 (3 0 0) and 49.5 0 (2 1 3) originate from calcium hydroxyapatite (HAp). Peaks at 16.9 0 , 18.2 0 , 23.1 0 and 43.0 0 derived from tigecycline. The FT-IR spectra shown in Figure 1b are observed doublets with maxima at 1,035 and 1,092 cm -1 , which are the most intense and originate from phosphate groups, and by a triplet with maxima at somewhat lower frequencies of at 1,760 cm -1 is attributed to C=O vibration from PLGA. The band at 1,521 cm -1 corresponds to the most intense peaks from tigecycline C 29 H 39 N 5 O 8 .
The microstructure of CP/PLGA and CP/PLGA/TG composite biomaterial was studied by AFM. Fig. 2 shows the morphology of the the CP/PLGA, CP/PLGA/TG0.6 and CP/PLGA/TG5 composite biomaterial prepared according to experimental procedures.
It was established by linear AFM analysis that the average particle diameter of this composite varied from 65 to 95 nm. 
Lactate dehydrogenase assay
All doses of TG greater than 50μg/mL on days 1, 2 and 3 resulted in an increased (p < 0.001) release of LDH compared to that of the control cells ( figure 4) . Although the data collected on days 1 and 2 showed a similar downward trend when the osteoblasts were treated with 0.5 μg/mL, 5 μg/mL TG, there have been no significant differences from the controls. As far as the time effect at each concentration of TG is concerned, the LDH activity did not significantly change at any concentration of the antibiotic during the observation period. The inhibitory activity of the diluents and their effect on the standard curve did not allow for the quantification of the amount of TG. Table 1 . FTIR spectrum is shown in Figure 1b confirmed the existence of HAp, TG and PLGA phase in the synthesized powder.
Discussion
The AFM image of the composite without tigecycline is shown in Fig. 2a and it indicates an average particle diameter of around 65 nm. The AFM morphology of the composite containing 0.6% and 5% of tigecycline is shown on Fig. 2b, c . Undoubtedly, the increase in the tigecycline content within the composite leads to the increased average particle diameter up to 95nm. In accordance with the XRD and FTIR results, CP particles coated with tigecycline-loaded PLGA were obtained. In our previous studies it was shown that the average particle size ranges of the nano-sized powder between 65 and 95 nm [7] .
Although the efficacy of the local antibiotic delivery systems is beyond dispute, the effect of high doses of antibiotics on local tissues is not well covered in relevant literature. The literature data indicate that increased antibiotic concentrations are accompanied with an increase in toxicity, suggesting that higher doses of the antibiotic may be better for the control of the infection; however, they are by no means benign [34] . It is important to take into consideration that most local delivery systems release a very high dose of antibiotics; in some cases the concentration is higher than 1000 times the MIC 90 [35] [36] [37] [38] .
To our knowledge, the present study has demonstrated the inhibitory effects of pure TG and the TG released from tigecycline-loaded CP/PLGA on osteoblasts in vitro for the first time. In the interpretation of our data, we have noted important caveats. First, we focused on the cytotoxicity and did not evaluate the cellular function in detail. The full bio programme has been beyond the scope of this paper. In addition, we evaluated the effect of the antibiotics in an in vitro system and our findings may not be directly applicable to an in vivo situation.
We have shown that the TG treatment at serum and bone concentrations achieved in a conventional intravenous antibiotic therapy 0.5 μg/ml -5 μg/ml neither yields toxic effects nor causes morphological change in osteoblasts in vitro [31, 37] . A concentration of tigecycline one-hundred-fold higher than MIC 50 for coagulase-negative staphylococci (CNS) did not cause negative effects on osteoblasts, which indicates that tigecycline could be used as a part of MDDS [39] . Higher concentrations, 250 μg/ml and above, caused high toxic effect and impaired normal osteoblastic morphology, indicating a fibroblastic rather than osteoblastic phenotype, maybe in a sense of dedifferentiation. The effect of the concentrations of TG, 500-or 1000-fold higher than MIC 50 for CNS, indicates that a MDDS based on TG could be compatible only if it had a well controlled antibiotic release rate. The cytotoxic and cytostatic effects of tetracycline on osteoblasts could be explained by a mitochondrial energetic impairment.
Tetracycline is known to inhibit the bacterial protein synthesis, as well as the eukaryotic protein synthesis and protein synthesis of isolated mitochondria [37, [40] [41] [42] . Significant morphological changes of cells in spread, cell membrane, and extensions were also detected with the use of other antibiotics (ciprofloxacin, vancomycin) over the dose 100 μg/ml [43] .
We have demonstrated that there was no impact on the percentage of viable osteoblasts incubated with CP/PLGA in the first 24 h, which is in accordance with our earlier research [44] . Low cytotoxicity values are probably the consequence of high compatibility of both constituents of the biocomposite material. The investigation of the time effect on each sample showed that the extracts from CP/PLGA increased significantly the LDH activity at each time point, but this activity was no more than two folds higher than that of the controls. Faster degrading polymers, like low-molecularweight PLGA or PLA, can give rise to a cytotoxic reaction due to the production of acidic degradation products [45] [46] [47] .
Compared to the corresponding controls at each time point, CP/PLGA/TG0.6 did not reveal cytotoxic effects. During the first day, eight percent of the total TG was released, calculated 9.6 µg of TG; [7] this concentration of TG did not cause cytotoxic effects.
The lower LDH activity in the cells incubated with CP/PLGA/TG0.6 than that in the cells incubated with CP/PLGA can be explained by a positive proliferation effect of tetracycline on osteoblasts [40] . The mechanisms underlying the effects of tetracyclines on osteoblastic cells remain unclear. However, tetracyclines can inhibit collagenase and/or the breakdown of collagen under a variety of conditions. These events might result in improved osteoblastic behaviour, having in mind that a stable collagenous matrix is known to play a significant role in the osteoblastic proliferation/differentiation sequence [48] [49] [50] . CP/PLGA/TG5 significantly decreased the LDH activity from 24 to 72 h. This can be explained by the high TG release in the first day and its deleterious effect on osteoblasts. During the first day, 20% of the total TG was released -namely, 200µg of TG. The highest release rate during the first day is related to the fact that a great amount of the antibiotic is adsorbed on the surface of nanoparticles, which is the consequence of the synthesis procedure. The zones of inhibition around the samples indicate that biologically active TG remains in the sample for three weeks. The quantification and the release mechanism of TG from implants in vivo and in vitro, important for potential preclinical applications, were dealt with in our previous study [7] . 
Conclusions
